Subcategory Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Fiscal Year: 2010

Download 2010 Medical/Pharmacologic projects (EXCEL)
This subcategory includes research on drugs (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, melatonin, and stimulants) to treat autism and its co-occurring conditions, as well as medical therapies such as transcranial magnetic stimulation (TMS).
Graph: The subcategories for Question 4 illustrate the many approaches to treatments and interventions supported by autism research funders. The largest amount of funding supported projects to develop Model systems and therapeutic targets (35%), followed by research on Behavioral interventions (29%). Medical/Pharmacologic interventions received 16% of funding, classroom-based interventions (Educational) received 10% of funding, and Technology-based interventions and supports received 7% of funding. The subcategories with the smallest amounts of funding included Occupational, physical, and sensory-based (2%) and Complementary, dietary, and alternative (1%).
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Strategic Plan Objective Institution
3/3-Atomoxetine placebo and parent training in autism Smith, Tristram Q4.S.F University of Rochester
Clinical Trials Network Staff Member Q4.L.A Autism Speaks (AS)
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Stein, Peter Q4.L.A University of Medicine & Dentistry of New Jersey
Pharmacotherapy of pervasive developmental disorders Stigler, Kimberly Q4.L.C Indiana University-Purdue University Indianapolis
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders Swedo, Susan Q4.L.A National Institutes of Health